Key result
Betaxolol reduces ambulatory daytime BP vs. verapamil, despite both drugs lowering office BP.
Why the study?
Does betaxolol compared to verapamil improve office and ambulatory blood pressure in patients with uncomplicated essential hypertension?
RCT (n=17)
randomly allocated
Does betaxolol compared to verapamil improve office and ambulatory blood pressure in patients with uncomplicated essential hypertension?
Betaxolol significantly reduces both office and ambulatory blood pressure, whereas verapamil only significantly reduces office blood pressure in patients with uncomplicated essential hypertension.
Answers are grounded in this paper and cite their sources.
Betaxolol may be preferred for sustained BP control; challenges reliance on office BP alone as primary endpoint in hypertension RCTs.
The purpose of this study was to compare in the individual hypertensive patient the blood pressure lowering effect of a beta-blocking agent i.e. betaxolol with that of a calcium entry blocker, i.e. verapamil. The antihypertensive efficacy of the drugs was evaluated both at the physician's office and by monitoring ambulatory daytime blood pressure using a portable blood pressure recorder (Remler M2000). Seventeen patients with uncomplicated essential hypertension (aged 35-67 years) were treated for two consecutive 6-week periods with either betaxolol, 20 mg/day or a slow-release formulation of verapamil, 240-480 mg/day. The sequence of treatment phases was randomly allocated and a 2-week wash-out period preceded each treatment. Both betaxolol and verapamil had a significant blood pressure lowering effect when assessed at the physician's office. However, ambulatory recorded blood pressures were significantly reduced only with betaxolol. In the presence of a physician, the best responders to betaxolol tended to be also the best responders to verapamil, whereas there was no relationship between the fall in ambulatory recorded blood pressure observed during betaxolol and the corresponding fall during verapamil administration. The blood pressure response to both betaxolol and verapamil was not related to age.
No takes yet. Share an insight, caveat, or question.
Waeber et al. (1988) conducted an RCT in uncomplicated essential hypertension (n=17). Betaxolol vs. Verapamil (slow-release formulation, 240-480 mg/day) was evaluated on Office and ambulatory daytime blood pressure. Betaxolol significantly reduced ambulatory daytime blood pressure, whereas verapamil did not, despite both drugs significantly lowering office blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: